At Medicalgorithmics, we blend technology and human care to elevate patient safety, optimize trial efficiency, and deliver accurate results. Partner with a trusted team experienced in supporting diverse and complex clinical trials globally.
Leverage cutting-edge AI algorithms that detect arrhythmias, measure QT, PR, and QRS intervals swiftly and precisely.
AI-driven quality checks identify and mitigate ECG data artifacts, ensuring robust and reliable outcomes.
Immediate identification of potentially life-threatening arrhythmias through advanced, continuous ECG monitoring.
Benefit from comprehensive human review ensuring clinical interpretation and decision-making integrity.,
Tailor AI parameters specifically to your clinical trial’s unique needs and patient demographics, optimizing sensitivity and specificity.
Commitment to transparent, unbiased, and ethical AI practices in ECG monitoring, ensuring patient safety and regulatory compliance.
Efficiently centralize ECG data for streamlined trial operations, reducing complexity and improving trial timelines.
Robust reporting and documentation meeting FDA, EMA, ensuring global regulatory standards.
Immediate identification of potentially life-threatening arrhythmias through advanced, continuous ECG monitoring.
Randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of AC01 in patients with heart failure with reduced ejection fraction (HFrEF).
Evaluate the response to a 12-week treatment with OATD-01 as a reduction of granulomatous inflammation in pulmonary parenchyma evaluated by [18F]FDG PET/CT imaging in subjects with active pulmonary sarcoidosis-Idiopatic Pulmonary Fibrosis.
Multicentre prospective cohort study where patients will receive up to 14 days of continuous ECG monitoring by wearing a portable monitoring device, starting within 72 hours after noncardiac surgery.
SAFE is an international multicentre RCT of concomitant surgical atrial fibrillation (AF) ablation in patients with paroxysmal or persistent AF undergoing cardiac surgery.
Background Sinus node dysfunction (SND) and atrioventricular block (AVB) are significant diagnostic and therapeutic problems. The primary method of their treatment is cardiac pacemaker implantation (PM). Although PM remains the main therapeutic approach for most patients with SND/AVB, long-term PM therapy can be associated with various limitations, complications, and the need for device and electrode replacement. There is increasing evidence for the effectiveness of an alternative approach to functional bradycardia associated with excessive vagal activation – cardioneuroablation (CNA). The method leads to the alleviation or complete resolution of bradycardia symptoms, as well as reflex syncope, providing an opportunity to discontinue PM therapy.
About us
Our History
Management Team
Partners
Work with us
Job offers
Recommend an employee
Application form
